NewsBenzingaReported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients Benzinga 2026.10.19 06:51 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
